Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?

Bibliography

• Barrios V, Escobar C. Is a new crash coming? J Hypertens Open Access 2012;1:e105
   Google Scholar
• Lewington Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Crim MT, Yoon SS, Ortiz E, et al. National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes 2012;5:343-51
   PubMed Web of Science ®Google Scholar
• Stephens MM, Fox BA, Maxwell L. Therapeutic options for the treatment of hypertension in children and adolescents. Clin Med Insights Circ Respir Pulm Med 2012;6:13-25
   PubMedGoogle Scholar
• Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007;50:299-305
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
   PubMed Web of Science ®Google Scholar
• Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012;126:2105-14
   PubMed Web of Science ®Google Scholar
• McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011;183:1007-13
   PubMed Web of Science ®Google Scholar
• Llisterri JL, Rodriguez-Roca GC, Escobar C, et al. on behalf of the Working Group of Arterial Hypertension of the Spanish Society of Primary Care Physicians (Group HTASEMERGEN); and the PRESCAP 2010 investigators. Treatment and blood pressure control in Spain during 2002 – 2010. J Hypertens 2012;30:2425-31
   PubMed Web of Science ®Google Scholar
• Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010;28:2196-203
   PubMed Web of Science ®Google Scholar
• Kastarinen M, Antikainen R, Peltonen M, et al. Prevalence, awareness and treatment of hypertension in Finland during 1982 – 2007. J Hypertens 2009;2788:1552-9
   Google Scholar
• Mancia G, De Backer G, Dominiczack A, et al. 2007 guidelines for the management of arterial hypertension: the. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: theTask Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. August 2011. Available from: www.nice.org.uk/guidance/CG127
   Google Scholar
• Escobar C, Barrios V. An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. Expert Opin Drug Metab Toxicol 2013;9:847-58
   PubMed Web of Science ®Google Scholar
• Barrios V, Coca A, Escobar C, et al. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice. Expert Rev Cardiovasc Ther 2012;10:159-66
   PubMedGoogle Scholar
• Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Prieto L, Herranz I. Adverse events in clinical trials: is a new approach needed? Lancet 2008;372:535-6
   PubMed Web of Science ®Google Scholar
• Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 2012;8:133-43
   PubMedGoogle Scholar
• Miura SI, Okabe A, Matsuo Y, et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013;36:134-9
   PubMed Web of Science ®Google Scholar
• Tamura K, Ohsawa M, Kanaoka T, et al. What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension? Hypertens Res 2013;36:107-8
   PubMed Web of Science ®Google Scholar
• Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011;336:801-8
   PubMed Web of Science ®Google Scholar
• Miura SI, Matsuo Y, Nakayama A, et al. Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Edarbi®. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002293/WC500119204.pdf
   Google Scholar
• Preston RA, Karim A, Dudkowski C, et al. Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment. Clin Pharmacokinet 2013;52:347-58
   PubMed Web of Science ®Google Scholar
• De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Healt Risk Manag 2012;8:299-305
   PubMedGoogle Scholar
• Bönner G, Bakris GL, Sica D, et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013;27:479-86
   PubMed Web of Science ®Google Scholar
• Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012;35:552-8
   PubMed Web of Science ®Google Scholar
• Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011;13:467-72
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011;13:81-8
   PubMed Web of Science ®Google Scholar
• White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011;57:413-20
   PubMed Web of Science ®Google Scholar
• Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011;45:1506-15
   PubMed Web of Science ®Google Scholar
• Quinn Baumann P, Zaman AK, McElroy-Yaggy K, Sobel BE. The efficacy and tolerability of azilsartan in mice with left ventricular pressure overload or acute myocardial infarction. J Cardiovasc Pharmacol 2013;61:437-43
   PubMed Web of Science ®Google Scholar
• Zaman AK, McLean DL, Sobel BE. The Efficacy and Tolerability of Azilsartan in Obese Insulin Resistant Mice with Left Ventricular Pressure Overload. J Cardiovasc Pharmacol 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• French CJ, Zaman AK, Sobel BE. The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques. J Cardiovasc Pharmacol 2011;58:143-8
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Suzuki S, Saitoh S, Takeishi Y. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction. Biol Pharm Bull 2013;36:1326-31
   PubMed Web of Science ®Google Scholar
• Kajiya T, Ho C, Wang J, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011;29:2476-83
   PubMed Web of Science ®Google Scholar
• Kusumoto K, Igata H, Ojima M, et al. Antihypertensive, insulin sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011;669:84-93
   PubMed Web of Science ®Google Scholar
• Lastra G, Santos FR, Hooshmand P, et al. The novel angiotensin II receptor blocker azilsartan medoxomil ameliorates insulin resistance induced by chronic angiotensin II treatment in rat skeletal muscle. Cardiorenal Med 2013;3:154-64
   PubMed Web of Science ®Google Scholar
• Zhao M, Li Y, Wang J, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab 2011;13:1123-9
   PubMed Web of Science ®Google Scholar
• Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007;20:579-86
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Gradman AH, Parisé H, Lefebvre P, et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013;61:309-18
   PubMed Web of Science ®Google Scholar
• Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000;9(9 Suppl):2-6
   PubMedGoogle Scholar
• Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008;8:45-50
   PubMed Web of Science ®Google Scholar
• Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124-31
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother 2008;9:129-36
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Candesartan in the treatment of hypertension: what have we learnt in the last decade? Expert Opin Drug Saf 2011;10:957-68
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol 2010;24:3-8
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64
   PubMed Web of Science ®Google Scholar
• Roush GC, Halford TR, Guddati AK. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012;59:1110-17
   PubMed Web of Science ®Google Scholar
• Dorsch MP, Gillespie BW, Erickson SR, et al. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-94
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8
   PubMed Web of Science ®Google Scholar
• Riess W, Dubach UC, Burckhardt D, et al. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol 1977;12:375-82
   PubMed Web of Science ®Google Scholar
• McAinsh J, Bastain W, Young J, Harry JD. Bioavailability in man of atenolol and chlorthalidone from a combination formulation. Biopharm Drug Dispos 1981;2:147-56
   PubMed Web of Science ®Google Scholar
• Cheng JWM. Azilsartan/chlorthalidone combination therapy for blood pressure control. Integr Blood Press Control 2013;6:39-48
   PubMedGoogle Scholar
• Shuster JE, Bleske BE, Dorsch MP. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. Vasc Health Risk Manag 2012;8:381-7
   PubMedGoogle Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
   PubMed Web of Science ®Google Scholar
• Sica D, Bakris GL, White WB, et al. Blood pressure lowering efficacy of the fixed dose combination of azilsartan and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012;14:284-92
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012;125:1229
   PubMed Web of Science ®Google Scholar
• Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorthiazide in stage 2 systolic hypertension. Hypertension 2012;60:310-18
   PubMed Web of Science ®Google Scholar
• Pierini D, Anderson KV. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. Ann Pharmacother 2013;47:694-703
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13
   PubMed Web of Science ®Google Scholar
• Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011;7:605-22
   PubMedGoogle Scholar